Latest filings (excl ownership)
S-3/A
Shelf registration (amended)
25 Apr 24
DEFA14A
Additional proxy soliciting materials
23 Apr 24
DEF 14A
Definitive proxy
23 Apr 24
S-3/A
Shelf registration (amended)
23 Apr 24
S-3/A
Shelf registration (amended)
15 Apr 24
EFFECT
Notice of effectiveness
9 Apr 24
S-3
Shelf registration
3 Apr 24
8-K
Pulse Biosciences Reports Business Updates and Fourth Quarter & Full Year 2023 Financial Results
28 Mar 24
S-3
Shelf registration
28 Mar 24
10-K
2023 FY
Annual report
28 Mar 24
8-K
Pulse Biosciences Announces FDA 510(k) Clearance for its CellFX® nsPFA™ Percutaneous Electrode System
11 Mar 24
8-K
Other Events
14 Feb 24
8-K
Regulation FD Disclosure
9 Jan 24
8-K
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX® nsPFA™ Cardiac Clamp
2 Jan 24
8-K
Submission of Matters to a Vote of Security Holders
22 Dec 23
8-K
Pulse Biosciences Announces First-in-Human Procedures with its Novel CellFX™ Nanosecond Pulsed Field Ablation (nsPFA™) Cardiac Catheter
20 Dec 23
DEF 14A
Definitive proxy
27 Nov 23
8-K
Regulation FD Disclosure
27 Nov 23
8-K
Pulse Biosciences Files 510(k) Submission with U.S. FDA for its CellFX nsPFA Percutaneous Electrode
21 Nov 23
PRE 14A
Preliminary proxy
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
8-K
Pulse Biosciences Reports Business Updates and Third Quarter 2023 Financial Results
13 Nov 23
8-K
Departure of Directors or Certain Officers
12 Sep 23
EFFECT
Notice of effectiveness
31 Aug 23
CORRESP
Correspondence with SEC
29 Aug 23
UPLOAD
Letter from SEC
18 Aug 23
S-3
Shelf registration
11 Aug 23
10-Q
2023 Q2
Quarterly report
10 Aug 23
8-K
Pulse Biosciences Reports Business Updates and Second Quarter 2023 Financial Results
10 Aug 23
8-K
Other Events
20 Jul 23
SD
Conflict minerals disclosure
31 May 23
8-K
Departure of Directors or Certain Officers
30 May 23
10-Q
2023 Q1
Quarterly report
11 May 23
8-K
Pulse Biosciences Reports Business Updates and First Quarter 2023 Financial Results
11 May 23
S-8
Registration of securities for employees
10 May 23
8-K
Pulse Biosciences, Inc. Announces Planned Redemption of Warrants
10 May 23
8-K
Entry into a Material Definitive Agreement
9 May 23
8-K
Departure of Directors or Certain Officers
5 May 23
8-K
Pulse Biosciences Announces $65 Million Private Placement
1 May 23
DEFA14A
Additional proxy soliciting materials
14 Apr 23
Latest ownership filings
SC 13D/A
DUGGAN ROBERT W
15 Dec 23
4
ROBERT W DUGGAN
14 Dec 23
4
ROBERT W DUGGAN
13 Dec 23
4
ROBERT W DUGGAN
12 Dec 23
4
ROBERT W DUGGAN
11 Dec 23
4
ROBERT W DUGGAN
8 Dec 23
4
ROBERT W DUGGAN
7 Dec 23
4
ROBERT W DUGGAN
6 Dec 23
4
ROBERT W DUGGAN
5 Dec 23
4
ROBERT W DUGGAN
4 Dec 23
SC 13D/A
DUGGAN ROBERT W
4 Dec 23
4
ROBERT W DUGGAN
1 Dec 23
4
ROBERT W DUGGAN
30 Nov 23
4
ROBERT W DUGGAN
20 Nov 23
4
Kevin Patrick Danahy
17 Nov 23
4
Mitchell E. Levinson
17 Nov 23
4
Mahkam Zanganeh
15 Nov 23
4
ROBERT W DUGGAN
9 Nov 23
4
Kevin Patrick Danahy
3 Nov 23
4
DARRIN UECKER
3 Nov 23
4
Mitchell E. Levinson
3 Nov 23
4
ROBERT W DUGGAN
28 Aug 23
4
ROBERT W DUGGAN
27 Jul 23
4
Kevin Patrick Danahy
14 Jul 23
4
DARRIN UECKER
14 Jul 23
4
Mitchell E. Levinson
14 Jul 23
4
ROBERT W DUGGAN
7 Jul 23
4/A
DARRIN UECKER
6 Jul 23
4/A
Mitchell E. Levinson
6 Jul 23
4/A
Mahkam Zanganeh
6 Jul 23
4
ROBERT W DUGGAN
16 Jun 23
4
Mahkam Zanganeh
13 Jun 23
4
Mitchell E. Levinson
13 Jun 23
4
DARRIN UECKER
13 Jun 23
4
ROBERT W DUGGAN
6 Jun 23
4
Manmeet Singh Soni
6 Jun 23
4
Shelley D Spray
6 Jun 23
4
Mahkam Zanganeh
6 Jun 23
4
den Broek Richard van
6 Jun 23
SC 13D/A
DUGGAN ROBERT W
11 May 23